scholarly journals A new oral kallikrein inhibitor for long‐term prophylaxis of hereditary angioedema

Allergy ◽  
2021 ◽  
Author(s):  
Inmaculada Doña ◽  
María José Torres
Keyword(s):  
Hereditary Angioedema ◽  
Kallikrein Inhibitor

scholarly journals Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

2021 ◽  
Vol 11 (4) ◽  
Author(s):  
Henriette Farkas ◽  
Marcin Stobiecki ◽  
Jonny Peter ◽  
Tamar Kinaciyan ◽  
Marcus Maurer ◽  
...  
Keyword(s):  
Hereditary Angioedema ◽  
Open Label

scholarly journals Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Konrad Bork ◽  
John T. Anderson ◽  
Teresa Caballero ◽  
Timothy Craig ◽  
Douglas T. Johnston ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hereditary Angioedema ◽  
Clinical Management ◽  
Disease Burden ◽  
The United States ◽  
Consensus Meeting ◽  
Consensus Statements ◽  
Consensus Report

Abstract Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient’s frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE. Methods A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting. Results Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient’s QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden. Conclusion This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE.

scholarly journals Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study

2021 ◽  
Vol 147 (2) ◽  
pp. AB145
Author(s):  
Kim Paes ◽  
Jonathan Bernstein ◽  
Hilary Longhurst ◽  
Emel Aygoren-Pursun ◽  
Hong Ren ◽  
...  
Keyword(s):  
Hereditary Angioedema ◽  
Extension Study ◽  
Open Label ◽  
Prior Use ◽  
Open Label Extension

SAFETY AND EFFICACY OF LONG-TERM SUBCUTANEOUS C1-INHIBITOR REPLACEMENT THERAPY FOR PREVENTION OF HEREDITARY ANGIOEDEMA ATTACKS

2018 ◽  
Vol 121 (5) ◽  
pp. S34 ◽  
Author(s):  
T. Craig ◽  
H. Longhurst ◽  
M. Cicardi ◽  
B. Zuraw
Keyword(s):  
Replacement Therapy ◽  
Hereditary Angioedema ◽  
C1 Inhibitor ◽  
Safety And Efficacy

Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: Comparison of treated and untreated patients☆☆☆★

1997 ◽  
Vol 99 (2) ◽  
pp. 194-196 ◽  
Author(s):  
M CICARDI ◽  
R CASTELLI ◽  
L ZINGALE ◽  
A AGOSTONI
Keyword(s):  
Side Effects ◽  
Hereditary Angioedema

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients

2008 ◽  
Vol 100 (2) ◽  
pp. 153-161 ◽  
Author(s):  
Konrad Bork ◽  
Anette Bygum ◽  
Jochen Hardt
Keyword(s):  
Hereditary Angioedema ◽  
Long Term Survey

scholarly journals Outcomes of long term treatments of type I hereditary angioedema in a Turkish family

2017 ◽  
Vol 92 (5) ◽  
pp. 655-660 ◽  
Author(s):  
Gulsen Akoglu ◽  
Belgin Kesim ◽  
Gokhan Yildiz ◽  
Ahmet Metin
Keyword(s):  
Hereditary Angioedema ◽  
Type I ◽  
Turkish Family
Sign in / Sign up

Export Citation Format

Share Document